Posted by Erin Schwartz on January 05, 2012
Our friends at the CML Advocates Network, Jan Geissler and Giora Sharf have, once again, diligently produced their report “ASH 2011: Key news on CML from a patients' perspective” and we are pleased to share it with all of you.
Jan begins the report by sharing these sentiments:
“Like every year in December, about 21.000 hematologists and health professionals (as well as a small group of patient advocates) convened at the Annual Meeting of the American Society of Hematology (ASH) to hear latest news from research in leukemias, lymphomas and other blood disorders.
We have attended the scientific CML sessions at ASH 2011 and are now summarizing the most important presentations and posters, complemented by a patients' perspective. This report covers key presentations on Nilotinib, Dasatinib, Bosutinib, Ponatinib, DCC-2036, Imatinib-Interferon combination, STOP studies, as well as some studies on CML and diabetes or fatigue.”
Read the CML Advocates Network's full report to find out about updates in CML, from the patient perspective.